Axovant Screens First Patients in Phase 3 MINDSET Study on RVT-101 for Alzheimer’s Disease

Axovant Screens First Patients in Phase 3 MINDSET Study on RVT-101 for Alzheimer’s Disease
Clinical-stage biopharmaceutical company, Axovant Sciences Ltd., recently announced it has screened the first batch of patients for MINDSET, an international Phase III clinical trial exploring RVT-101 as a candidate treatment for Alzheimer’s disease. The company also reported the US Food and Drug Administration’s decision to grant MINDSET a Special Protocol Assessment (SPA). MINDSET was designed as a

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *